Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Impaired Fasting Glucose

A study evaluated the effects of the DPP-4 inhibitor vildagliptin on insulin sensitivity and β-cell function in 22 subjects with impaired fasting glucose (IFG). Over 6 weeks of treatment, vildagliptin significantly improved insulin sensitivity, β-cell function, and postprandial glucose control. These benefits were not maintained after treatment cessation, suggesting that vildagliptin may help delay the progression to diabetes in high-risk individuals.